Guided Therapeutics (GTHP) Retained Earnings (2010 - 2025)

Guided Therapeutics has disclosed Retained Earnings across 16 years of filings, most recently posting -$157.1 million for Q4 2025.

• Retained Earnings for Q4 2025 came in at -$157.1 million, down 2.18% year-over-year; the trailing twelve-month figure through Dec 2025 was -$157.1 million (down 2.18% YoY), and the FY2025 annual result was -$157.1 million, down 2.18% from the prior year.
• Retained Earnings came in at -$157.1 million for Q4 2025 at Guided Therapeutics, down from -$155.8 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$140.6 million in Q1 2021 to a low of -$157.1 million in Q4 2025.
• The 5-year median for Retained Earnings is -$150.3 million (2023), against an average of -$149.0 million.
• Across the five-year window, Retained Earnings sank 1046546.38% in 2021 and fell 1.57% in 2024, its largest moves.
• Guided Therapeutics' Retained Earnings stood at -$142.4 million in 2021, then retreated by 3.49% to -$147.4 million in 2022, then slipped by 2.55% to -$151.1 million in 2023, then decreased by 1.71% to -$153.7 million in 2024, then decreased by 2.18% to -$157.1 million in 2025.
• The last three Retained Earnings figures came in at -$157.1 million (Q4 2025), -$155.8 million (Q3 2025), and -$155.0 million (Q2 2025), per Business Quant data.